View in EDS

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Saved in:
Bibliographic Details
Title: 333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial
Authors: Cottu, P.H.1 (AUTHOR), De Laurentiis, M.2 (AUTHOR), Marchetti, P.3 (AUTHOR), Coltelli, L.4 (AUTHOR), Califaretti, N.5 (AUTHOR), Debled, M.6 (AUTHOR), Patil, S.7 (AUTHOR), Evron, E.8 (AUTHOR), Duhoux, F.P.9 (AUTHOR), Menon-Singh, L.10 (AUTHOR), Wu, J.11 (AUTHOR), Zhou, K.12 (AUTHOR), Salvador Bofill, J.13 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv118-v118. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdz242.028